Introduction {#s0005}
============

Dietary intake of inorganic nitrate has for more than half a century been considered potentially harmful due to its bioconversion to nitrite and carcinogenic nitrosamines [@bib1; @bib2]. After the discovery of nitric oxide (NO) as a biological signaling molecule nitrate and nitrite have been used as stable surrogate markers of NO synthase-derived NO [@bib3]. More recently an alternative pathway of NO generation was described in which serial reduction of nitrate and nitrite to NO and other bioactive nitrogen intermediates occurs [@bib4]. This NO synthase (NOS) independent pathway relies on retention of nitrate anions through salivary concentration from the plasma. Nitrate is reduced to nitrite by oral commensal bacteria, swallowed, absorbed and further reduced to NO and other bioactive nitrogen oxides in blood and tissues [@bib5; @bib6]. A number of studies have demonstrated robust NO-like bioactivity after ingestion of nitrate. These include a reduction in blood pressure [@bib7; @bib8], inhibition of platelet aggregation [@bib8; @bib9], improved vascular function [@bib10] and increased mitochondrial efficiency [@bib11]. The crucial involvement of oral bacteria in nitrate bioactivation is evident from experiments using an antibacterial mouthwash, or if the test persons avoid swallowing of saliva after nitrate ingestion. Under these conditions the nitrate effects are greatly reduced or lost [@bib8; @bib12; @bib13; @bib14]. A paradox regarding the proposed harmful effects of dietary nitrate is the fact that vegetables are the greatest source of this anion. Long term longitudinal studies have specifically identified green leafy vegetable intake, which is the dominant nitrate source, as inversely proportional to the risk of diabetes in aging females and cardiovascular disease in males [@bib15; @bib16].

The recent studies showing beneficial cardiovascular and metabolic effects of dietary nitrate in animal models and humans have been short term or acute. Other long term dietary studies have been performed investigating the putative toxicity of nitrate and nitrite using high doses of these anions [@bib17; @bib18; @bib19; @bib20; @bib21]. This study aimed at determining the long term effects of dietary nitrate intake in mice at doses similar to what can be achieved in humans by a diet rich in vegetables. During nitrate or matched sodium chloride supplementation of approximately 18 months, we looked at the parameters for metabolic, cardiovascular and inflammatory differences.

Materials and methods {#s0010}
=====================

Animals {#s0015}
-------

All animal procedures in this study were in strict adherence to the *Guide for the Care and Use of Laboratory Animals* as adopted by the U.S. National Institutes of Health and were approved by the Regional Animal Care and Use Committee of Stockholm, Sweden. Six week-old male C57Bl/6 mice (*n*=27) were obtained from Charles River (Sulzfeld, Germany). After 1 week acclimatization the animals were fed low nitrate chow (0.06 µg/g NO~3~, D06041501DW, Research Diets, New Brunswick, NJ, USA) and housed in rooms at 22 °C with a 12/12 day-night cycle. After 3 months, the animals were separated into similar weight groups of 14 and 13 with 1 mM sodium chloride (NaCl) or 1 mM sodium nitrate (NaNO~3~) respectively in the drinking water. Over this period, weight and food and water uptake were monitored ([Fig. 1](#f0005){ref-type="fig"}). The health of the animals was monitored using an institutional physiological checklist and if behavior resulted in a combined score of 0.4 the animal was sacrificed and blood and organs collected. Seven animals were sacrificed due to poor health and four animals died of natural causes during the experiment.

Materials {#s0020}
---------

All chemicals not specified were obtained from Sigma-Aldrich at the highest grade available.

Body composition {#s0025}
----------------

Body composition by dual energy X-ray absorptiometry (DeXA) was measured under isoflurane anesthesia using the PIXImus imager (General Electric, Niskayuna, NJ, USA) according to manufacturer\'s instructions [@bib22].

Intraperitoneal glucose tolerance test {#s0030}
--------------------------------------

Animals were starved for 6 h, separated individually, fasting blood glucose recorded (Freestyle Lite, Abbott Diabetes Care, Alameda, CA, USA). Following an intraperitoneal injection of [d]{.smallcaps}-glucose (2 g/kg BW) blood glucose was measured at 15, 30, 60 and 120 min [@bib22].

Intraperitoneal insulin tolerance test {#s0035}
--------------------------------------

Under non-fasting conditions the mice were separated and initial blood glucose measurement was taken from the tail, an intraperitoneal insulin load (0.75 IE kg^−1^) was administered and blood glucose was measured at 15, 30, 45, 60, 75, 90, and 120 min [@bib22].

Blood pressure {#s0040}
--------------

Blood pressure was monitored using the Coda High Throughput Noninvasive Tail Monitoring System (Kent Scientific, Torrington, CT, USA) following the manufacturer\'s protocol. Systolic, diastolic and mean arterial pressure measurements were collected over 5 consecutive days and averaged [@bib22].

Indirect calorimetry {#s0045}
--------------------

Individual mouse oxygen consumption was measured using an INCA indirect calorimeter (Somedic, Horby, Sweden). Animals were placed in the equipment between 5 pm and 6 pm and underwent 36 h at 24 °C and 24 h at the thermoneutral 34 °C maintaining a 12/12 light dark cycle consistent with animal room timing.

Mitochondrial isolation {#s0050}
-----------------------

After euthanizing the mouse, the soleus muscle was extracted, weighed and immediately added to 1 mL of ice-cold isolation medium: 100 mM sucrose, 100 mM KCl, 50 mM Trizma--HCl, 1 mM KH~2~PO~4~, 0.1 mM EGTA and 0.2% BSA (weight). The sample was homogenized with a pair of scissors (≈5 min) and left for sedimentation. The supernatant was removed and the sample was washed by adding new isolation medium again followed by sedimentation. This procedure was repeated twice whereupon isolation medium containing bacterial protease (0.2 mg/mL) was added and the sample was left on ice for 30 s followed by low intensity vortexing during 30 s. After repeating the procedure once more, the sample was transferred to a Potter-Elvehjem homogenizer and further homogenized at 125 rpm during approximately 2 min. The sample was then transferred to a falcon-tube pre-filled with 3 mL of isolation medium and centrifuged at 700*g* for 10 min (4 °C). The supernatant was collected and further centrifuged at 10,000*g* during 10 min. The buffy coat of extramitochondrial debris was carefully washed away with isolation medium followed by resuspension in isolation medium. After a new centrifugation step at 7000*g* for 5 min, the pellet was further washed and resuspended in mitochondrial preservation medium (0.6 µl/mg tissue sample) containing 0.5 mM EGTA, 3 mM MgCl~2~, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH~2~PO~4~, 20 mM HEPES, 110 mM sucrose, 1 g/L BSA, 20 mM histidine, 20 µM vitamin E succinate, 3 mM glutathione, 1 µM leupeptin, 2 mM glutamate, 2 mM malate and 2 mM Mg--ATP.

Mitochondrial respirometry {#s0055}
--------------------------

All mitochondrial experiments were performed at 37 °C in a 2-channel respirometer (Oroboros Oxygraph O2-K; Oroboros Instruments, Innsbruck, Austria). Respiration medium contained 0.5 mM EGTA, 3 mM MgCl~2~, 60 mM K-lactobionate, 20 mM taurine, 10 mM KH~2~PO~4~, 20 mM HEPES, 110 mM sucrose and 1 mg/mL BSA. Mitochondrial substrates used for complex I respiration were pyruvate (5 mM) and malate (2 mM). Stepwise titration of carbonylcyanide 4-(trifluoromethoxy)phenylhydrazone (FCCP) was performed in order to measure maximal uncoupled respiration. The produced adenosine triphosphate per consumed oxygen (P/O-ratio) was determined at 10 kPa in the presence of 2 mM ATP. Adenosine diphosphate was infused with a microinjection pump (Tip2K; Oroboros Instruments) at nonsaturating concentrations to produce a respiration rate corresponding to approximately half maximal state 3 respiration. The ADP infusion rate was divided by the oxygen consumption in order to calculate the P/O-ratio. Corrections were made for back diffusion of oxygen into the respiration chamber, oxygen dissolved in the infused ADP solution and oxygen consumption by the oxygen electrode.

Vascular reactivity {#s0060}
-------------------

Isolation and dissection of carotids were performed as described previously [@bib23]. In brief, bilateral carotid arteries were isolated and placed in physiological salt solution (PSS, composition in mM: 119 NaCl, 4.7 KCl, 1.6 CaCl~2~, 1.2 KH~2~PO~4~, 1.2 MgSO~4~, 25.1 NaHCO~3~, 5.5 glucose, 0.026 EDTA). Arteries were dissected and mounted in myograph chambers (model 620M, Danish Myo Technology, Denmark), and isometric tension was recorded (Powerlab 4/30, A D instruments, Australia). After mounting, vessels were equilibrated for 20 min in PSS bubbled with carbogen (95% O~2~; 5% CO~2~) at 37 °C, pH 7.4. Resting tension of the arteries was set in accordance with Mulvany\'s normalization procedure [@bib24]. Following a second equilibration, 0.1 mol/L KCl was applied to assess arterial ring viability. Carotid arteries were then assessed for their dose response to acetylcholine (ACh, 10^−9^--10^−4^ mol/L), sodium nitroprusside (SNP, 10^−9^--10^−4^ mol/L), and 30 min contractile response to the non-selective NO-synthase inhibitor N^ω^-nitro-[l]{.smallcaps}-arginine methyl ester (L-NAME, 100 µM) after preconstriction with phenylephrine (PE, 0.1 or 1 µM). Arteries were washed three times and allowed to stabilize between experimental segments[.]{.smallcaps}

Plasma markers {#s0065}
--------------

Insulin ELISAs were purchased from Mercodia (Uppsala, Sweden). Multiplex proinflammatory 7 cytokine kit and custom made metabolic kit (Glucagon, active GLP-1, Insulin, and Leptin) were purchased from Mesoscale Discoveries (Rockville, MD, USA). T3 and T4 ELISA kits were purchased from Calbiotech (Spring Valley, CA, USA). cGMP EIA was purchased from GE Healthcare. All kits were run according to manufacturers\' instructions. Plasma nitrite and nitrate and urinary nitrate were analyzed by HPLC (ENO-20) and autosampler (840, EiCom, Kyoto, Japan). Plasma was extracted using methanol (1:2) then centrifuged for 10 min 4 °C 10g. Urine samples were initially diluted (1:50) using carrier solution containing 10% methanol. Nitrate and nitrite were separated by reverse phase/ion exchange chromatography followed by nitrate reduction to nitrite by cadmium and reduced copper. The nitrite was then derivatized using Griess reagent to form diazo compounds and analyzed by detection at 540 nm.

Plasma amino acids {#s0070}
------------------

Urea cycle amino acids and methyl-arginines were analyzed as previously described with a few modifications [@bib25]. Briefly, after thawing samples on ice, 25 µl of plasma were crashed with 225 µl of 0.2% formic acid in isopropanol containing the internal standard (0.73 µM of N~4~-Arginine). Afterwards samples were vortexed for 30 s and centrifuged at 8000*g* for 10 min. Finally 5 µl of the supernatant was analyzed by liquid chromatography tandem mass spectrometry (LC--MS/MS). Separation was performed on an ACQUITY UPLC System from Waters Corporation (Milford, MA, USA) using an Atlantis HILIC Silica 3 µm (150×2.1 mm^2^) column from Waters. Mobile phases consisted of 0.2% formic acid in ACN:MeOH (75:25, v/v) and 0.2% formic acid in water. The flowrate was set at 400 µl/min. The chromatographic gradient was set as follows: 0 min, 100% A; time range 0→8 min, 100→60% A (linear decrease); time range 8--9 min, 60→50% A (linear decrease); time range 9→9.8 min 50% A (isocratic range), time range 9.8→10.0, 50→100% A (linear increase). The column was then allowed to equilibrate at 100% A for 3 min. Detection was performed using a Waters Xevo® TQ triple quadrupole equipped with an Electrospray Ion Source working in positive mode. For the quantification, the following SRM transitions were used: Arginine (175.1→70.1), Ornithine (133.1→70.1), Citrulline (176.1→70.1), ADMA (203.1→46.0), SDMA (203.1→172.1) and N~4~-Arginine (179.1→71.1).

NADPH oxidase activity {#s0075}
----------------------

Segments of the heart, liver and kidney were cut from frozen tissue and homogenized in PBS using a Bullet Blender (Next Advance, Inc. Averill Park, NY, USA) following the manufacturer\'s protocol. Particulate was centrifuged, supernatant was collected and diluted, and then 50 mM of lucigenin and 0.1 mM NADPH added. Superoxide production was measured every 3 s for 3 min with the AutoLumat LB953 Multi-Tube Luminometer (Berthold Technologies, Bad Wildbad, Germany) [@bib22].

Statistics {#s0080}
----------

Comparison between groups was calculated by student\'s *t*-test. For comparison of 2 groups over time a 2-way ANOVA followed by Bonferroni post-hoc test was used. Survival was calculated using Log-rank test. All statistical calculations were made using Graphpad Prism (La Jolla, CA, USA). A *p* value\<0.05 was considered significant. All results are shown as mean±SEM.

Results {#s0085}
=======

Metabolic changes {#s0090}
-----------------

### Weight and body composition {#s0095}

Past publications have found that nitrate intake inhibited weight gain [@bib20; @bib26; @bib27; @bib28]. In contrast with these findings we found no differences in average weight or weight gain over the 17 months of nitrate supplementation when compared to control ([Fig. 2](#f0010){ref-type="fig"}A). Only animals that survived until final sacrifice were included in this weight comparison. Food and water consumption, measured periodically over the length of the study, were similar between groups (not shown). There were no differences in fat and lean body composition between groups when measured at 2, 12, and 17 months of supplementation ([Fig. 2B](#f0010){ref-type="fig"}). At final sacrifice, there were no significant differences in the weight of the heart, liver, pancreas, kidney, and gonadal adipose tissue ([Table 1](#t0005){ref-type="table"}). One mouse in each group had hepatomegaly when they were sacrificed due to poor health.

### Glucose and insulin tolerance tests {#s0100}

Short-term dietary nitrate has previously been shown to improve glucose metabolism in endothelial NO synthase (eNOS) deficient mice with features of metabolic syndrome [@bib29]. To see if there were any differences in glucose handling, intraperitoneal glucose tolerance tests (IPGTT) were run periodically throughout the experiment. There were no differences in the area under the curve of IPGTTs performed at 5, 7, 10, 14 and 17 months of treatment ([Fig. 3](#f0015){ref-type="fig"}A) (5 month results shown in [Fig. 3](#f0015){ref-type="fig"}B). This held true for the fasting glucose levels (Control 7.34±0.14 mmol/L vs Nitrate 7.45±0.14 mmol/L; *p*=0.563). An intraperitoneal insulin tolerance test at 17 months of treatment showed improved insulin responsiveness in the nitrate treated group as measured by percent change from basal glucose level ([Fig. 3](#f0015){ref-type="fig"}C) and area under the curve of the individual tests ([Fig. 3](#f0015){ref-type="fig"}D).

### Metabolic markers in plasma {#s0105}

The improved insulin tolerance test suggested changes in hormone levels, so we looked at plasma hormone levels related to metabolism by multiplex ELISA. There were no differences in plasma leptin, glucagon, active GLP-1 and insulin levels ([Table 2](#t0010){ref-type="table"}). Closer look at the individual results indicated one obese nitrate animal skewed the insulin results away from significance ([Fig. 4](#f0020){ref-type="fig"}A). This mouse had insulin resistance as identified in the nitrate treated animals by the diamond in the individual IPITT AUC ([Fig. 3](#f0015){ref-type="fig"}D), fasting insulin level ([Fig. 4](#f0020){ref-type="fig"}A) and the HOMA-IR figures ([Fig. 4](#f0020){ref-type="fig"}B). Statistical calculation without this animal led to significantly decreased insulin and HOMA insulin resistance score in the dietary nitrate group.

Prior research had identified nitrate intake as down regulating plasma levels of thyroid hormones thyroxine (T4) and triiodothyronine (T3) [@bib20; @bib26; @bib30]. Our experiment found total T3 trended to being decreased in the nitrate treated group and this remained after calculating the ratio of T3 to T4 ([Table 2](#t0010){ref-type="table"}).

### Oxygen consumption {#s0110}

Research in humans has shown that acute nitrate intake reduces resting metabolic rate and oxygen cost during exercise, and these effects are coupled to improved skeletal muscle mitochondrial efficiency [@bib11; @bib31; @bib32]. Indirect calorimetry was measured in a subset of animals at 11 months of treatment to see if there were changes in oxygen consumption under both ambient and thermoneutral conditions. Thermoneutral conditions remove the requirement for the animals to expend energy maintaining their body temperature. There were no significant differences in oxygen consumption, respiratory quotient, or delta oxygen under normal (24 °C, data not shown) or thermoneutral (34 °C) conditions ([Table 3](#t0015){ref-type="table"}). At sacrifice, soleus muscle was isolated from the mice and mitochondrial efficiency was measured. Longterm nitrate treatment did not change the respiratory control ratio, the P/O ratio, leak, state 3, or 4 or uncoupled respiration ([Table 4](#t0020){ref-type="table"}).

Cardiovascular parameters {#s0115}
-------------------------

### Blood pressure {#s0120}

Acute dietary nitrate has been shown to decrease blood pressure in humans [@bib7; @bib8]. Blood pressure was measured by tail cuff monitoring after 16 months of nitrate treatment. No differences between the treatment groups were identified in the systolic, diastolic or mean arterial pressure (MAP) ([Table 5](#t0025){ref-type="table"}).

### Vascular reactivity {#s0125}

At final sacrifice, ex vivo reactivity of the carotid artery was carried out in a myograph. There were no differences in the endothelium-independent dilatory response to sodium nitroprusside between controls and nitrate treated mice ([Fig. 5](#f0025){ref-type="fig"}A). The endothelium-dependent response to acetylcholine was also similar between the two groups ([Fig. 5](#f0025){ref-type="fig"}B). Treatment with non-selective NO synthase inhibitor L-NAME for half an hour induced a similar sized contraction in both groups ([Fig. 5](#f0025){ref-type="fig"} C). Taken together, the results demonstrate that long term dietary nitrate had no adverse effects on vascular reactivity[.]{.smallcaps}

### Vascular plasma markers {#s0130}

Analysis of nitrogen oxides in the final plasma collection indicated no difference in plasma nitrite or nitrate between the treatment groups ([Fig. 6](#f0030){ref-type="fig"}A and B). Two animals with liver nodules skewed the control group towards increased plasma nitrite levels inducing a trend towards significance ([Fig. 6](#f0030){ref-type="fig"}A). Plasma cGMP has been shown to be increased after acute nitrate dosing, though there were no differences after long term nitrate treatment ([Fig. 6](#f0030){ref-type="fig"}C). To confirm that the animals were ingesting nitrate, we measured urinary nitrate collected from the bladder at final sacrifice ([Fig. 6](#f0030){ref-type="fig"}D). Urine collected directly from the bladder at sacrifice contained similar amounts of nitrate in both groups. However, in the control group one mouse with liver nodules skewed the control data. Exclusion of this animal led to twice as high levels of urinary nitrate in the treated animals.

Previous research has identified a crosstalk between nitrate and decreased eNOS function as evidenced by changes in plasma amino acid concentrations and aortic eNOS phosphorylation [@bib33]. Nitric oxide is produced by the reaction of oxygen and [l]{.smallcaps}-arginine with the eNOS yielding [l]{.smallcaps}-citrulline. There were no significant differences in total arginine, citrulline and ornithine concentrations or in ratios of citrulline to arginine, or ornithine to citrulline ([Table 6](#t0030){ref-type="table"}). Dimethyl arginines, which are inhibitors of eNOS function, were also analyzed with no significant differences in their plasma concentration ([Table 6](#t0030){ref-type="table"}).

### Inflammation and oxidative stress {#s0135}

#### Inflammatory markers in plasma {#s0140}

During aging there is a natural increase in plasma inflammatory markers [@bib34]. Using a pro-inflammatory multiplex ELISA we found no differences in interferon-gamma, interleukin-1beta, interleukin-6, KC/GRO, (an interleukin-8 homolog found in mice), and interleukin 12p70 ([Table 7](#t0035){ref-type="table"}). The anti-inflammatory interleukin-10 was significantly decreased in the nitrate supplemented group. The overall values were in the same range as we found in a batch of 6--9 month-old wildtype animals (unpublished data).

#### NADPH oxidase activity in tissue {#s0145}

Oxidative stress due to increased NADPH oxidase activity is often increased with aging and chronic inflammation. NADPH oxidase activity was compared in heart, liver and kidney tissue. There were no differences between the treatment groups in tissue NADPH oxidase activity, supporting the lack of inflammation changes found in the plasma cytokine measurements ([Fig. 7](#f0035){ref-type="fig"}).

Survival {#s0150}
--------

We made a survival curve of the animals that died or had to be euthanized due to poor health. The results suggested a slightly better median survival with nitrate supplementation vs the control group (Control 600.5 days vs Nitrate 640.5 days, *p*\<0.05). This should be confirmed in a larger study.

Discussion {#s0155}
==========

This study in normal healthy mice shows that dietary nitrate does not have any obvious adverse long-term effects, an important finding considering the major health concerns associated with nitrate intake. Though there are continued concerns of nitrate intake inducing adverse health effects in humans, our study found limited differences from control mice after close to a year and a half of high dietary nitrate. Our calculations extrapolating average mouse nitrate consumption to a 75 kg person would yield approximately 26.1 mg nitrate per day on the control diet and 350 mg/day on the nitrate diet. These doses fall at the ends of the average intake range of 40 mg to 120 mg/day published in World Health Organization advisory documents [@bib35], combined from multiple national nitrate intake studies. A study from the Netherlands, analyzing nitrate and nitrite content in a duplicate sample of individual 24 h food and water intake in 1994, found a range of 1--322 mg/day with a median of 53 mg nitrate per day and approximately 20% of the volunteers exceeded 150 mg/day [@bib36]. While the control is on the low side of published ranges, it is a plausible level due to increased societal reliance on processed food, often containing negligible nitrate content. Vegetarians often ingest more nitrate so the treatment regimen may be more representative of a vegetarian diet.

Prior research on the toxicity and carcinogenicity of nitrate in rats used doses 10--50 times that used in this study, without salt matched controls [@bib17; @bib18; @bib20; @bib21]. Even at such exorbitant doses Chow et al. (1980) saw no survival difference when compared to control, while Maekawa et al. (1982) saw more animals in the nitrate group surviving at termination but no differences in cancer incidence of various organs. A more recent study using a dose 10 times our nitrate dose over a shorter treatment period, found nitrate led to decreased weight gain and decreased plasma fasting insulin, T4 and T3 levels [@bib20]. Our study showed no difference in group weight or weight gain over the course of 17 months of nitrate treatment.

The animals used in our study were healthy wildtype mice, which started to be afflicted by aging related issues and death around 20 months of age. The overall health of the mice may have prevented our finding beneficial effects due to long-term nitrate supplementation. The study, initially developed to document these beneficial effects, was modified towards a survival experiment due to lack of differences. Larsen et al. (2014) found acute nitrate did not change the glucose tolerance response in healthy volunteers, though there are other parameters such as blood pressure and oxygen consumption where acute nitrate induced changes. The long term supplementation may have also affected the nitrate homeostasis of the animals, which is supported by the lack of differences in final plasma nitrite, nitrate and cGMP. Urinary nitrate disposal increased from 7 months (data not shown) of treatment to 17 months reflecting a modified disposal potentially matching the nitrate intake. These changes could also have affected the ability to identify changes in blood pressure, vascular reactivity, indirect calorimetry and mitochondrial efficiency which were analyzed after 10 months of nitrate treatment. Conversion of nitrate to nitrite in the oral cavity and ingestion is imperative to achieve blood pressure improvement; which may be modified under extended nitrate treatment and homeostasis modifications. The lack of differences in nitrite concentration bears this out. In contrast to organic nitrate where continuous treatment leads to endothelial dysfunction, there were no adverse effects on vascular function as measured by blood pressure or ex vivo carotid response after long-term inorganic nitrate supplementation.

The plasma concentration of tri-iodothyronine (T3) and IL-10 were reduced, IL-10 significantly, compared to control after long term nitrate treatment. Whether these findings are coincidence or part of a program of overall signaling changes in the body remains to be determined. Previous studies analyzing T3 concentration and inflammatory cytokines in patients with euthyroid illness have conflicting results with one study finding no association between T3 and cytokines [@bib37], while another reported decreased T3 and increased IL-10 and IL-6 [@bib38].

T3 and T4 concentrations affect metabolic function and have been shown to be decreased in people with hypothyroidism and increased in hyperthyroidism. Body mass index changes inversely to plasma T3 concentration [@bib39; @bib40]. Weight loss studies looking at T3 concentration before and after weight loss show that plasma T3 was lower compared to controls [@bib41; @bib42; @bib43]. Pourhassan et al. (2014) following a cohort of non-smoking adults between 2 and 4 years, stratified the volunteers by weight loss, weight gain or weight stable and found concomitant decreases in T3 and insulin in the weight loss group and a T3 concentration increase in the weight gain group. In contrast to studies using supra-physiological nitrate intake in rats which found decreased plasma T3 and T4 concentrations with decreased weight gain [@bib20; @bib26; @bib27; @bib30; @bib44; @bib45; @bib46], there was no significant weight or weight gain difference between groups at any point during the 17 month period. Combining our findings of improved insulin response, decreased plasma T3 and plasma insulin in most of our mice, opens the possibility that nitrate treatment lowers the threshold for metabolic response.

The decrease in anti-inflammatory IL-10 is another counterintuitive event. In general IL-10 increases are described to lead to better insulin response, while IL-6 leads to insulin resistance [@bib47]. IL-10 has been shown to be decreased in response to acute inflammation [@bib48; @bib49] and multiple sclerosis [@bib50] inversely to the increased pro-inflammatory cytokines. There was no increase in inflammatory signaling in our experiments. Jadert et al. (2012) showed that acute nitrate decreased inflammatory response to signaling for neutrophil extravasation and recruitment without a change in overall clearance of a bacterial load [@bib51]. Nitric oxide and nitrite have been shown to negatively modulate iNOS and NADPH oxidase activity [@bib52]. As speculated with T3 maybe nitrate modulates inflammatory signaling lowering the basal cytokine expression. Future experiments will need to explore this possibility.

Conclusions {#s0160}
===========

The findings in this study do not support any long-term toxic effects of dietary nitrate. Several of the beneficial effects described previously with short-term nitrate supplementation could not be reproduced in this model of natural aging. Intriguing results of decreased plasma insulin, and IL-10 and improved insulin tolerance and survival will need to be confirmed in larger follow up studies. Studies exploring different doses of nitrate supplementation will yield better indications for optimal supplementation.
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![Experimental timeline. Diagram of the experimental procedures on the mice over the course of the experiment. The green squares indicate period of supplementation. NaCl, sodium chloride; NaNO~3~, sodium nitrate; DeXA, dual energy X-ray absorptiometry; IPGTT, intraperitoneal glucose tolerance test; BP, blood pressure; IPITT, intraperitoneal insulin tolerance test.](gr1){#f0005}

![Weight and body composition. Average weight (A) and lean and fat body composition (B) at different time points over the course of the study. Control represented by open bars and nitrate by green bars. Average weight consists of the 8 animals per group. In the body composition graph the numbers above the bars indicate animals per group. Values are means ± SEM.](gr2){#f0010}

![Glucose and insulin tolerance tests. Area under the curve (AUC) of the intraperitoneal glucose tolerance test (IPGTT) as a percentage of the 5 month IPGTT in control animals (A), and group average IPGTT curve at 5 month of supplementation (B). Intraperitoneal insulin tolerance test (IPITT) as percent of basal glucose (C) and area under the curve for each of the individual mice measured in arbitrary units (AU) (D). Control represented by open bars or symbols and nitrate by green bars or symbols. Values are means ± SEM. ^⁎^*p*\<0.05.](gr3){#f0015}

![Plasma insulin and HOMA. Plasma insulin (A) and HOMA score for insulin resistance (B) calculated from blood glucose and insulin level at sacrifice and shown as arbitrary units (AU). Values are means ± SEM.](gr4){#f0020}

![Ex vivo vascular reactivity. Carotid rings were analyzed for their response to sodium nitroprusside (SNP) (A), acetylcholine (ACh) (B) or 30 minute application of L-NAME (C). Control represented by open squares and nitrate by green squares. Values are means±SEM. PE=phenylephrine[.]{.smallcaps}](gr5){#f0025}

![Nitrogen oxides and cGMP. Final plasma nitrite (A), nitrate (B), cGMP (C), and urinary nitrate (D). Note the split *y*-axis on graphs B and D. Data from two animals in the control groups with liver nodules are shown as diamonds. Values are means±SEM. Ns=non-significant.](gr6){#f0030}

![Tissue NAPDH oxidase activity. NADPH oxidase activity was measured by NADPH addition to heart, liver and kidney homogenates inducing superoxide production and reaction with lucigenin. Control represented by open bars and nitrate by green bars. Values are means ± SEM.](gr7){#f0035}

###### 

Final body weight and organ weight.

                      Control (8)    Nitrate (8)    *p*-Value
  ------------------- -------------- -------------- -----------
  Final body weight   38.46 ± 1.76   36.48 ± 1.99   0.469
  Heart               0.205 ± 0.00   0.213 ± 0.00   0.310
  Liver               1.993 ± 0.14   2.017 ± 0.20   0.924
  Pancreas            0.175 ± 0.01   0.185 ± 0.01   0.576
  Kidney              0.540 ± 0.02   0.534 ± 0.02   0.835
  Gonadal fat         1.432 ± 0.17   1.382 ± 0.20   0.854

###### 

Plasma hormone markers.

                     Control (8)     Nitrate (8)     *p*-Value
  ------------------ --------------- --------------- -----------
  Leptin (pg/L)      7.542 ± 1.55    8.399 ± 2.99    0.803
  Glucagon (pg/mL)   187.9 ± 29.5    208.3 ± 43.2    0.702
  GLP-1 (pg/mL)      28.72 ± 3.49    33.42 ± 7.77    0.589
  Insulin (pg/L)     3.881 ± 0.61    2.627 ± 0.76    0.222
  Total T3 (nM)      2.712 ± 0.12    2.199 ± 0.22    0.060
  Total T4 (nM)      56.85 ± 3.75    54.98 ± 2.54    0.648
  T3/T4 Ratio        0.048 ± 0.002   0.040 ± 0.003   0.052

###### 

Metabolic cages: thermoneutral.

                          Control (6)   Nitrate (5)   *p*-Value
  ----------------------- ------------- ------------- -----------
  Inactive period                                     
   Oxygen consumption     20.52±1.779   20.00±1.828   0.843
   Respiratory quotient   0.726±0.054   0.778±0.026   0.438
   Delta oxygen           8.602±0.727   8.379±0.813   0.842
   CO~2~ production       14.43±0.624   15.36±1.113   0.468
                                                        
  Active period                                       
   Oxygen consumption     32.42±1.969   33.16±4.784   0.881
   Respiratory quotient   0.596±0.027   0.677±0.075   0.299
   Delta oxygen           13.63±1.025   13.70±1.812   0.974
   CO~2~ production       19.33±1.207   21.76±2.385   0.362

###### 

Mitochondrial respiration.

                           Control (5)   Nitrate (5)   *p*-Value
  ------------------------ ------------- ------------- -----------
  RCR                      5.553±0.794   4.551±0.398   0.301
  P/O Ratio (pmol s^−1^)   1.232±0.132   1.215±0.078   0.910
  Leak respiration         0.410±0.190   0.328±0.067   0.538
  State 3 respiration      6.414±0.952   4.471±0.787   0.154
  State 4 respiration      0.497±0.117   0.467±0.082   0.839
  Uncoupled respiration    6.933±1.888   5.180±0.629   0.404

RCR=Respiratory control ratio.

Leak, States 3 and 4, and uncoupled respiration units are pmol /s/µg.

###### 

Blood pressure.

              Control (10)   Nitrate (12)   *p*-Value
  ----------- -------------- -------------- -----------
  Systolic    95.8±1.49      98.1±2.42      0.452
  Diastolic   66.8±1.32      66.9±1.47      0.972
  MAP         76.1±1.26      76.9±1.74      0.730

###### 

Plasma amino acids.

                    Control (8)   Nitrate (8)   *p*-Value
  ----------------- ------------- ------------- -----------
  Arginine (µM)     85.97±10.15   78.21±6.275   0.526
  Ornithine (µM)    41.79±4.252   45.06±5.976   0.662
  Citrulline (µM)   43.59±2.418   42.50±2.734   0.770
  Cit/Arg           0.544±0.047   0.575±0.062   0.699
  Orn/Cit           0.965±0.092   1.063±0.139   0.562
  SDMA (µM)         0.302±0.036   0.266±0.009   0.344
  ADMA (µM)         1.984±0.085   1.884±0.005   0.322

###### 

Plasma cytokines (pg/mL).

              Control (8)   Nitrate (8)   *p*-Value
  ----------- ------------- ------------- --------------------------------------------
  INF-gamma   1.897±0.602   1.120±0.114   0.245
  IL-1beta    5.708±0.298   6.824±0.616   0.125
  IL-6        49.07±14.68   32.52±3.421   0.309
  IL-10       57.04±5.991   35.79±5.329   0.018[⁎](#tbl7fnStar){ref-type="table-fn"}
  KC/GRO      60.26±12.83   54.97±4.552   0.708
  IL-12p70    216.9±83.63   135.6±8.981   0.360

*p*\<0.05
